Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.

ABSTRACT: Background: The pandemic of coronavirus disease 2019 (COVID-19) resulted in grave morbidity and mortality worldwide. There is currently no effective drug to cure COVID-19. Based on analyses of available data, we deduced that excessive prostaglandin E₂ (PGE₂) produced by cyclooxygenase-2 was a key pathological event of COVID-19. Methods: A prospective clinical study was conducted in one hospital for COVID-19 treatment with Celebrex to suppress the excessive PGE₂ production. A total of 44 COVID-19 cases were enrolled, 37 cases in the experimental group received Celebrex as adjuvant (full dose: 0.2 g, bid; half dose: 0.2 g, qd) for 7-14 days, and the dosage and duration was adjusted for individuals, while seven cases in the control

SUBMITTER: Hong W 

PROVIDER: S-EPMC7703865 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature